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ABSTRACT 
 
 
 High prevalence rates of depression have been well documented in patients with chronic 
kidney disease (Egede, 2007; U.S. Renal Data System, 2013). Furthermore, depression seems to 
play a major role in the mortality and morbidity rates of this population (Kellerman, Christensen, 
Baldwin, & Lawton, 2010; U.S. Renal Data System, 2013). Therefore this study aimed to 
discover factors that may influence depression in this population. Ten end-stage renal disease 
(ESRD) patients’ depression scores were examined in relation to various sociodemographic 
measures. High depression scores had a significantly negative relationship with social 
functioning, overall quality of life, and age. A combined model of social functioning, sleep 
quality, and age provides a stronger prediction than any variable alone. Results suggest that 
targeting social functioning, sleep quality, and age should be the focus of future studies 
examining interventions of these factors as augmentations to current pharmacological treatments 
of depression in ESRD populations.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Depression affects many people around the world regardless of age, health, gender, and 
ethnicity. However, research has shown that those with chronic diseases such as end-stage renal 
disease (ESRD) show higher rates of depression and are more prone to depressive symptoms 
compared to the general public (Egede, 2007; U.S. National Library of Medicine, 2014; U.S. 
Renal Data System, 2013). Furthermore, within the ESRD population, it has been shown that 
higher levels of depression may be predictive of higher mortality rates (Kellerman et al., 2010; 
U.S. Renal Data System, 2013). These two findings point to the increased need to reduce 
depression in those with chronic diseases. The current study aims to provide more information 
about the relationship of depression with other individual factors in kidney disease patients. The 
ultimate goal is to use this information to develop better intervention strategies that can lower the 
depression levels of those with chronic diseases, which may lead to lower mortality and improve 
the quality of life in this population. 
 
Background 
 End-Stage Renal Disease (ESRD) is known as the fifth and final stage of Chronic Kidney 
Disease (CKD), and can be characterized by the individual requiring either a kidney transplant or 
some form of dialysis in order to live (U.S. National Library of Medicine, 2014). In 2011 it was 
estimated that nearly 400,000 people suffer from ESRD in the United States alone (U.S. Renal 
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Data System, 2013). Many times ESRD results from long-term kidney problems due to diabetes 
or hypertension, with diabetes accounting for one-third and hypertension accounting for one-
fourth of the ESRD incidents in 2011 (U.S. Renal Data System, 2013). Additionally, ESRD 
patients often suffer from a variety of comorbidities, including cardiovascular disease, 
depression, and malnutrition, with depression being one of the most prevalent in the population. 
Multiple studies estimate the prevalence of depression to be between 20% and 25% in ESRD 
patients, as compared to a 2% to 4% prevalence in the United States population (Chiang, Livneh, 
Yen, Li, & Tsai, 2013; Egede, 2007; Kimmel, Cukor, Cohen, & Peterson, 2007). This high 
prevalence of depression within the ESRD population warrants even more attention due to the 
link between depression and increased mortality rates in those with ESRD. Several studies show 
significant positive correlations between depression and mortality in the ESRD population, 
including some results that indicate depression is associated with nearly a 22% increase in 
mortality for depressed patients compared to those who do not suffer from depressive symptoms 
(Kellerman et al., 2010; van Dijk et al., 2012; Ver Halen, Cukor, Constantiner, & Kimmel, 
2012).  
 
Objectives of the Study 
The literature and statistics discussed in the previous section provide the rationale for 
setting the focus of the current study on depression and determining what factors play a role in 
the depression symptoms of this particular population. The main goal of the study is to provide 
more information on the roles of social functioning, quality of life, sleep quality, and length of 
time on dialysis in ESRD patients, to determine which factors may have the strongest 
relationship with depression in this population. With this information it is hoped that additional 
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treatments or care-taking strategies can be implemented that would promote the reduction of 
depression symptoms in ESRD patients, which may subsequently lower the mortality rate and 
increase quality of life. Furthermore, prolonging the lifespan of this population is crucial as it 
gives these patients more time to receive a transplant, which is well documented to have a 
tremendous effect on quality of life and life expectancy compared to dialysis patients (Álvares, 
Cesar, de Assis Acurcio, Andrade, & Cherchiglia, 2012; U.S. National Library of Medicine, 
2014; U.S. Renal Data System, 2013).  
The present study looks at perceived social functioning, quality of life, sleep quality, and 
age – factors studied previously in the literature. It adds to this literature by verifying previous 
findings, clarifying the literature on the effects of length of time on dialysis, while also 
contributing unique information by examining the effect of these factors combined. The 
following literature review examines each of the factors included in this study in detail, to 
understand what has previously been done and what is still missing from the literature.  
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CHAPTER II 
 
LITERATURE REVIEW 
 
 
Review of Related Studies 
 
Social Functioning 
 
 Past research on factors that influence depression in ESRD patients has focused primarily 
on psychosocial factors such as perceived social support. It is important to notice the focus of 
perceived support, as the depression symptoms observed are often a result of how much support 
the patient perceives, rather than the amount of support an objective measure might suggest. 
Additionally, it is also important to note that social support is a broad term used to encompass a 
range of social constructs. Many have argued that the term social support is not specific enough 
to be a reliable research measure, because it is a measure that includes too many factors that 
should be studied individually (Barrera, 1986; Cohen & McKay, 1984; Cohen & Wills, 1985; 
Heller, 1979). The present study heeds to these suggestions by studying a specific aspect of 
support (social functioning) to determine how it may be related to depression symptoms in 
ESRD patients, compared to common literature studies focusing on social support as a generic 
term. 
In one of the first studies examining social support as defined generically in ESRD 
patients, Christensen, Turner, Slaughter, and Holman (1989), grouped 57 ESRD patients into a 
high or low group based on their reported support levels. Christensen et al. (1989) found that 
those in the high social support group showed significantly lower depression and higher 
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psychological well-being levels compared to those in the low social support group. An additional 
study by Christensen and colleagues grouped subjects into a high support group and low support 
group, finding the group with low perceived support had a mortality rate of 58%, nearly three-
times higher than those with high perceived support with a rate of 18% (Christensen, Wiebe, 
Smith, & Turner, 1994). Several others have also documented the impact of perceived social 
support on depression. Chan and colleagues (2011) conducted a meta-analysis of 57 studies to 
examine the role of the most commonly studied psychosocial factors, such as social support 
(subjective and objective), stress, and personality attributes, in chronic dialysis patients to assess 
which factors had the most significant impact on depression levels. Results of this meta-analysis 
showed perceived social support, along with stress, to have significantly higher effect sizes than 
all other factors, .33 and .37 respectively, in a pooled sample that included nearly 6,000 subjects 
(Chan et al., 2011). 
 In addition to the ESRD population, more recent research has shown the relation between 
social support and depression to hold steady in otherwise healthy populations as well. Wang and 
Zhao (2012) studied the relationship between depression and social support by comparing a 
group of older adults (ages 60-80) diagnosed with major depressive disorder to a group of non-
depressed older adults in the same age group. Results showed that the depressed group showed 
significantly less perceived social support than the non-depressed group. Similar results were 
found in a study of depressed young adults (ages 16-21) with no comorbidities, where perceived 
social support was associated with lower levels of stress and depression (Raffaelli et al., 2013).  
In summary, perceived social support plays an important role in depression levels of 
ESRD patients. It is not yet known whether specific subtypes of support, such as social 
functioning are equally important in depression. As Barrera (1986) suggests, the use of more 
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specific measures of social support should provide a more accurate view of the relation between 
support and depression. 
 
Health Related Quality of Life 
Health related quality of life refers to a combination of both physical and mental health 
factors (Ware & Sherbourne, 1992), and is another factor that is thoroughly discussed in the 
literature of ESRD patients. Health related quality of life is often measured by subjective report, 
similar to perceived social support, as it is often the perceived physical or mental health that is of 
interest when studying depression. While a great amount of literature focuses on perceived social 
support, a considerable amount of research has also explored the overall health related quality of 
life of ESRD patients. In addition, a recent study suggests that health related quality of life is 
becoming an even more important factor to consider for today’s ESRD patients as medical 
advances have helped increase the life expectancy of patients on dialysis (Glover, Banks, Carson, 
Martin, & Duffy, 2011).  
With an increase in life expectancy, the quality of life in the ESRD population must be 
monitored more closely. To better monitor health related quality of life, it is crucial to 
understand what factors influence it in the ESRD population. In their study of 49 ESRD patients, 
Steele et al. (1996) found that depression was strongly correlated to health related quality of life 
scores, as measured by the Patient-Assessed Quality of Life index (PAQoL), and advised that the 
link between the two should be considered carefully when devising caretaking plans for this 
population. More recent research has further accentuated the relationship between depression and 
health related quality of life. In 2005, a study of 194 dialysis patients showed depression was 
correlated more highly with health related quality of life than any other psychosocial factor 
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included in the study (Vázquez et al., 2005). Perales-Montilla, Garcia-Leon, and Reyes-del Paso 
(2012) also found depression to be a significant predictor of low health related quality of life in a 
sample of ESRD patients. These results reflect the need to consider health related quality of life 
as a factor that may influence depression in the current study, to determine if it should be a target 
for caretaking strategies of those suffering from both depression and ESRD.  
 
Sleep Quality 
 Like poor health related quality of life, sleep disturbances are also frequently reported 
among ESRD patients (Brekke et al., 2013). Estimates from recent literature report between 65% 
and 75% of ESRD patients suffer from “poor sleep” as subjectively rated using the Pittsburgh 
Sleep Quality Index (PSQI), a commonly used measure of sleep quality in the ESRD literature 
(Brekke et al., 2013; Iliescu et al., 2003; Kusleikaite, Bumblyte, Razukeviciene, Sedlickaite, & 
Rinkunas, 2005). The high prevalence of sleep disturbances mark sleep quality as another target 
for inspection to determine if it has a role in predicting depression scores. An assortment of 
recent studies on ESRD patients’ sleep quality conclude that it does. Brekke et al. (2013) studied 
301 dialysis patients to determine the association between sleep quality, as measured by the 
PSQI, and depression. The PSQI measure characterizes “poor sleep” as a score of greater than 5 
out of 21 on a range of questions about patients’ sleep quality in the last month. The results 
showed “poor sleep” was significantly related to depression, and that “poor sleepers” scored 
significantly lower on mental components of health related quality of life measures than good 
sleepers.  In another study, self-reported cases of insomnia were found to be associated with 
higher depression levels (Paparrigopoulos, Theleritis, Tzavara, & Papadaki, 2009). Additionally, 
poor sleep quality may lead to more problems and higher depression in otherwise healthy adults 
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as well. In a large sample of over 3,000, “poor sleepers” assessed by the PSQI showed an 
increase in comorbidities (60%) compared to “good sleepers” (38%), while the proportion of 
depression increased significantly as sleep quality worsened (Hayashino et al., 2010). 
Collectively, this literature provides another possible link with depression that can be assessed 
through the present study, to determine if sleep quality should be another focus when considering 
ways to lower depression levels in the ESRD population.  
 
Length of Time on Dialysis 
 Unlike some of the other factors discussed thus far, length of time on dialysis is an 
important demographic factor in this population that is not often examined or discussed in the 
literature regarding the ESRD population. Early research reported a significant relationship 
between length of time on dialysis and self-reported depression (Kutner, Fair, & Kutner, 1985), 
and more recently, a study found a significant difference in the perceived consequences of 
treatment in participants with varying lengths of time on dialysis (Jansen et al., 2013). In this 
study, perceived consequences of treatment were assessed by the Treatment Effects 
Questionnaire which asks the participant to answer questions about the impact of side-effects due 
to treatment, how much their life revolves around the treatment, and whether the treatment 
“keeps them from enjoying themselves.” Results of this study showed that the perceived 
treatment consequences were significantly more negative for patients who were on dialysis for 
longer lengths of time (Jansen et al., 2013). These studies provide some evidence that length of 
time on dialysis may play a role in depression levels of ESRD patients. However, despite these 
findings the topic is still greatly understudied and needs to be further established in the literature. 
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Although evidence of a direct association between time on dialysis and depression scores 
is substantially understudied in the ESRD population, some studies have shown associations 
between time on dialysis and other factors that may be indirectly related to depression levels, 
such as adherence to treatment (Hudson, Fielding, Jones, & McKendrick, 1987). In contrast to 
length of time on dialysis, the association between adherence to medical treatment and 
depression in ESRD and other chronic disease populations is well documented in the literature 
(Bolkan et al., 2013; Sacco et al., 2007; Theofilou, 2013; Zhang et al., 2013). Collectively these 
findings provide evidence that length of time on dialysis could play an indirect role in depression 
levels.  
 
Age 
 Age, like gender, is a common demographic collected in research that it is included in 
nearly every study regardless of the topic. The same is true for ESRD and depression studies; 
however, the results of the literature in the particular area of depression in ESRD populations 
may not be as transparently logical compared to other studies examining age effects. Studies that 
include age effects in their studies on depression in ESRD populations have found some 
interesting results as to which age group is more depressed. A study by Laudanski, Nowak, and 
Niemczyk (2013) examined quality of life, depression, and coping strategies of ESRD patients to 
determine if there were any age related differences in the way younger (mean age = 47.1) and 
older adults (mean age = 68.3) cope with their disease. It was found that while both groups 
showed higher levels of depression than a healthy, age-matched control group, younger ESRD 
patients showed higher levels of depression, and more frequently used emotional preoccupation 
strategies to cope than the older patient group. Additionally, younger patients made significantly 
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more complaints about sleep disturbances, which correlate strongly with depression levels, as 
reviewed earlier. 
 Additional studies have found similar results in ESRD populations, in which age is 
negatively correlated with depression and other measures of mental health (Chilcot et al., 2011; 
Griva et al., 2014). With these studies in mind, it is of interest to look more closely at age and its 
relationship with depression. 
 
The Present Study 
 Many of the factors included in the present study have been shown in the literature to 
have either a direct, or possibly indirect, relationship with depression, providing the logic for 
including each of them in exploring some of the factors that might help better predict 
experiences of depression in ESRD patients. However, in the same way each of the factors is 
connected, they also each provide a unique target for intervention when it comes to the care of 
this population because they each examine the issue of depression from a different aspect. 
Therefore, the present study was designed to determine which of the factors included (social 
functioning, health related quality of life, sleep quality, length of time on dialysis, and age) or 
which combinations of these factors best predict levels of depression in ESRD patients.  
  
Hypotheses 
 Based on the previous review of the literature, the following hypotheses were explored in 
the present study. Depression scores in the present study were assessed using the Center for 
Epidemiologic Studies Depression Scale, Revised Version (CESD-R), which is detailed in the 
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following methodology section, as is the SF-36 Health Related Quality of Life questionnaire 
(SF-36) and Pittsburgh Sleep Quality Index (PSQI). 
 H1: Perceived social functioning, as measured by the SF-36 subscale, will have a 
significant negative relationship with depression scores. 
 H2: Overall health related quality of life, as measured by the SF-36, will have a 
significant negative relationship with depression scores. 
 H3: Quality of sleep, as measured by the PSQI, will have a significant positive 
relationship with depression scores, as in this measure, higher scores are equivalent to a poorer 
quality of sleep. 
 H4: Length of time on dialysis will have a significant positive relationship with 
depression scores. 
 H5: Age will have a significant negative relationship with depression scores. 
 H6: ESRD participants will score significantly differently from healthy controls on 
measures of depression, social functioning, health related quality of life, and sleep quality. 
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CHAPTER III 
 
METHODOLOGY 
 
 
Participants 
 A sample of ESRD participants was recruited between November, 2012, and February, 
2014, as part of a larger study (Tumlin, Harris, & Whitson, 2012) by a local kidney research 
institute (Southeastern Renal Research Institute, SERRI) in Chattanooga, Tennessee. Recruited 
participants were tested based on their availability, willingness to participate, and various 
inclusion and exclusion criteria. The full list of inclusion and exclusion criteria is included in 
Appendix A. Fifteen participants were recruited and qualified for testing during the study period; 
ten participants (66.7%) gave informed consent and completed the study. Two participants were 
excluded from the analysis on any model that included length of time on dialysis due to missing 
data, therefore the simple regression and multiple regression models that included length of time 
on dialysis were analyzed with only 8 participants. Demographic and medical data were 
collected after participants consented to this study, while all other participant data was collected 
at a single visit at the SERRI clinic prior to further tests included in the larger study (Tumlin et 
al., 2012) to ensure testing fatigue did not play a role in participants’ responses. Five healthy 
(non-kidney disease) controls, matched on age, gender, and race, were recruited from a 
community sample to compare the  kidney disease sample to the healthy sample on depression, 
social functioning, health related quality of life, and sleep quality.  
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Measures 
 
Demographics 
 
 Demographic and medical data for ESRD participants included age, gender, race, and 
length of time on dialysis. Of the ten kidney disease participants, eight were male and two were 
female, four were Caucasian and six were African American. The ESRD sample had a mean age 
of 56.6 (SD = 12.3) ranging from 36 to 73, and the mean time on dialysis was 75.5 months (SD = 
97.8) with a range of 3.2 to 251.4. The median time on dialysis was 29.9 months, which may be 
a more informative measure of central tendency due to the small sample size in this study. Of the 
five healthy control participants, four were male and one was female, four were Caucasian and 
one was African American. The mean age of the group was 54.4 (+/- 11.8) ranging from 42 to 
70.  
 
Center for Epidemiologic Studies Depression Scale, Revised Version 
 The Center for Epidemiologic Studies Depression Scale, Revised Version (CESD-R) is 
used to measure depression as defined by the American Psychiatric Association’s Diagnostic and 
Statistical Manual (DSM-IV) (Eaton, Smith, Ybarra, Muntaner, & Tien, 2004). The scale 
consists of 20 questions and measures depression symptoms on a Likert scale of 0 to 3 responses 
for all 20 questions, where 0 corresponds to the lowest level of depressive symptoms and 3 to the 
highest level of depression symptoms. A patient’s depression score is obtained by simply taking 
the sum of all responses for a possible score of 0 to 60. The diagnostic cut-off for exhibiting 
clinical depression symptoms is 16, with varying levels of diagnosis (mild, moderate, severe) for 
those scoring above the cutoff. For the purposes of this study, the overall score from 0 to 60 for 
each participant was used in the analyses to represent depression level. Reliability and validity 
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analyses for this scale have demonstrated high reliability with a Chronbach’s α of .928 and high 
convergent and divergent validity (Eaton et al., 2004; Van Dam & Earleywine, 2011).  
 
Short Form – 36 Health Related Quality of Life Questionnaire 
 The Short Form-36 Health Related Quality of Life Questionnaire (SF-36) is a measure of 
quality of life relating to health issues, particularly measuring mental and physical components 
(Ware & Sherbourne, 1992). The scale consists of 36 questions that assess eight subscales, 
including social functioning, and two main components of mental and physical health. All 
questions use a Likert scale, with each question varying in the range of responses (0-3, 0-5, 0-6). 
Scoring of the SF-36 for each component and subscale is achieved by converting the raw score to 
a percentage score, where a score of 100 represents the highest possible level of functioning and 
0 represents the lowest possible level of functioning. For the purposes of this study, the social 
functioning percentage score and the mean of all subscale percentage scores are used in analysis 
to represent perceived social functioning and overall quality of life, respectively. Reliability and 
validity estimates of the social functioning subscale and the questionnaire overall both show a 
Chronbach’s α of .85, and high convergent and discriminant validity (McHorney, Ware, Lu, & 
Sherbourne, 1994) .   
 
Pittsburgh Sleep Quality Index 
 The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire used to assess 
sleep quality and disturbances over the month prior to the subject taking the questionnaire 
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The questionnaire consists of nine 
questions, some of which are free quantitative responses about sleep time and latency, and others 
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on a Likert Scale from 0 to 3. The scale can be separated into seven components, or used as an 
overall measure that is equal to the sum of each component score. Component scores are 
computed on a 0 to 3 scale, while the overall score has a range from 0 to 21, where an overall 
score of 5 or greater indicates “poor sleep.” For the purposes of this study, the overall score from 
0 to 21 for each participant is used in the analyses to represent sleep quality. It is important, for 
interpretive purposes, to be mindful that a higher score indicates worse sleep quality for the 
PSQI. Reliability and validity analyses conducted by the creators of the questionnaire revealed 
strong reliability with an overall Chronbach’s α of .83, and significant convergent validity 
correlations (Buysse et al., 1989).   
 
Procedure 
 Participants were recruited at the SERRI clinic during a routine visit. After consenting, 
kidney disease participants were scheduled for an appointment at SERRI at a later date for data 
collection. Upon arrival at SERRI on the day of the appointment, participants were given a 
questionnaire packet including the PSQI, SF-36, and CESD-R in that order. After completing the 
packet, the participant’s involvement in this particular study was complete and they were free to 
continue with the procedures of the larger study (Tumlin et al., 2012). If participants completed 
the larger study, they were given $100 for their participation. Controls were recruited based on 
age, gender, and race match with a kidney disease participant and availability in the greater 
Chattanooga, Tennessee area. All healthy control data were collected in a single visit at The 
University of Tennessee at Chattanooga. Controls were not incentivized for their participation in 
the study. All data from ESRD participants and controls were entered into an encrypted 
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Statistical Package for Social Sciences file for analysis. All individuals involved in the collection 
or analysis of the data were HIPAA certified in the protection of human rights. 
  
Statistical Analysis 
 IBM’s SPSS version 21 for Macintosh (IBM Corporation, 2012) was used for all of the 
analyses in the study. First, an independent samples t-test was conducted to test for differences 
between the healthy and kidney disease samples on age and measures of social functioning, 
overall quality of life, sleep quality and depression. Age was tested here because not all ESRD 
participants were matched with a healthy control. The t-test was used to test for any significant 
difference in age between the control and kidney disease participants. Next, simple regressions 
for each variable included in the study were run for the kidney disease group. These regressions 
tested each factor’s relationship to depression scores. Finally, multivariate regression models 
were used to determine if any combination of variables added significantly to the prediction of 
depression scores in this sample. These models were compared to simple regression models to 
assess the uniqueness of each predictor while the other variables were held constant.  
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CHAPTER IV 
 
RESULTS 
 
 
Findings 
 
 An independent samples t-test analysis was conducted first to determine if there was a 
difference between the kidney disease sample and the healthy sample on measures of social 
functioning, health related quality of life, sleep quality, and age. The results of analyses 
comparing the groups are shown in Table 4.1. It is important to note that there was no significant 
difference between the groups in age. These results indicate that age should not confound the 
other variables included in the analysis. Results of the analysis also showed that kidney disease 
participants differed significantly from the healthy control participants on measures of social 
functioning, overall quality of life, and sleep quality (p < .05). Depression levels between the two 
groups were marginally significant (p = .075). 
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Table 4.1 
Independent Samples T-Test Results Between Kidney Disease and Control Group 
Factor Group Mean SD t p-value 
Age 
Healthy 54.4 11.8 
-.331 .746 
Kidney Disease 56.6 12.3 
Depression 
Healthy 5.2 4.0 
-1.938 .075 
Kidney Disease 15.8 1.4 
Social Functioning 
Healthy 95.0 14.5 
3.284 .010 
Kidney Disease 62.5 19.9 
Overall Quality of Life 
Healthy 82.1 3.3 
3.019 .033 
Kidney Disease 51.6 11.8 
Sleep Quality 
Healthy 4.5 11.2 
-3.529 .006 
Kidney Disease 11.8 27.0 
 
 
 Before the regression analysis, each variable was assessed for normality to determine if 
any transformations to the data were necessary. All tests of skewness and kurtosis indicated no 
need for transformations. Normal probability plots for each variable are shown in Appendix E.  
For the kidney disease group, the relationship between each of the variables and 
depression was analyzed using SPSS’s linear regression procedure. A univariate regression was 
conducted for each variable with depression. The results of these analyses are reported in Table 
4.2. The individual analyses showed both social functioning (p = .012) and overall quality of life 
(p = .007) to be significantly negatively related to depression scores. Age (p = .051) was found to 
have a marginally significant negative relationship, while sleep quality (p = .744) and length of 
time on dialysis (p = .193) were not significant. 
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Table 4.2 
Univariate Regression Analysis with Depression Results for Kidney Disease Participants 
Factor Pearson r p-value t p-value 
Social Functioning -.755 .006 -3.252 .012 
Overall Quality of 
Life 
-.783 .004 -3.564 .007 
Sleep Quality .119 .372 .338 .744 
Length of Time 
on Dialysis 
-.514 .096 -1.468 .193 
Age -.630 .025 -2.294 .051 
 
 
 Next, multivariate analyses were conducted to determine if any combination of variables 
served as a stronger predictor than any individual variable alone. Using SPSS’s linear regression 
procedure, a series of models were created to assess all combinations of the variables. Each 
model was compared on significance of the regression model, multiple r-square, and r-square 
change values to determine if the model added significantly to the previous model. Using this 
technique, 20 models were assessed, 7 of which were significant at a two-tailed p-value of less 
than .05. It was discovered that the model including social functioning, sleep quality, and age 
significantly predicted depression scores (p = .007) and accounted for the greatest amount of 
sample variance in the depression scores (r
2
 = .852, adjusted-r
2
 = .778) of all models. In this 
model, social functioning (t = -3.939, p = .008) and age (t = -2.685, p = .036) were significantly 
negatively related to depression scores, while sleep quality was marginally significant and 
positively related to depression scores (t = 2.429, p = .051). 
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Correlations of each variable are shown in Table 4.3. A model including the significant 
predictors from the univariate analysis (Social functioning, overall quality of life, age) was not 
significant, most likely due to multicollinearity (high correlation between variables). In a case of 
multicollinearity, the variable with the highest simple r is considered to have a stronger 
relationship. Therefore, if only one measure is available, the health related quality of life is the 
better measure in this study. In an additional note about the data analyses, sleep quality was not a 
significant predictor when used alone, however when controlling for two of the other variables 
(social functioning and age) it was. The variables that strengthen sleep quality’s relationship with 
depression are called suppressor variables. With the relationship being positive, this finding 
indicates that when social functioning and age are equal, those who have low sleep quality 
(higher PSQI score) have high levels of depression.  
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Table 4.3 
Simple Pearson r Correlations of Variables 
 
Depression 
Social 
Functioning 
Quality of 
Life 
Sleep 
Quality 
Time on 
Dialysis 
Age 
Depression 1 -.749 -.774 .308 -.514 -.569 
Social 
Functioning 
- 1 .907 -.026 .461 .225 
Quality of 
Life 
- - 1 -.218 .280 .245 
Sleep 
Quality 
- - - 1 .026 .103 
Time on 
Dialysis 
- - - - 1 .382 
Age - - - - - 1 
 
 
Summary of Hypothesis Testing 
   H1: Perceived social functioning, as measured by the SF-36 subscale, was expected to 
have a significant negative relationship with depression scores. This hypothesis was supported 
by the data analyses. In both univariate and multivariate regression models, high levels of 
perceived social functioning were significantly related to lower depression scores in the sample. 
 H2: Overall health related quality of life, as measured by the SF-36, was expected to 
have a significant negative relationship with depression scores. This hypothesis was supported 
by the data analysis. Similar to social functioning, in both univariate and multivariate regression 
models, high levels of overall quality of life were significantly related to lower depression 
scores. 
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 H3: Quality of sleep, as measured by the PSQI, was expected to have a significant 
negative relationship with depression scores. This hypothesis was partially supported by the data 
analysis. Quality of sleep was only significantly related to depression scores when its suppressor 
variables were included in a multivariate analysis. Social functioning, overall quality of life, as 
well as age acted as suppressor variables for sleep quality. When these factors were held 
constant, better quality of sleep was significantly related to lower depression scores.  
 H4: Length of time on dialysis was expected to have a significant positive relationship 
with depression scores. This hypothesis was not supported by the data analysis. In both 
univariate and multivariate regression models, length of time on dialysis was not significantly 
related to depression scores. 
 H5: Age was expected to have a significant negative relationship with depression scores. 
This hypothesis was supported by the data analysis. Although marginally significant (p = .051) 
in the univariate regression analysis, the multivariate analyses showed age to have a significant, 
negative relationship with depression scores, when social functioning and sleep quality were held 
constant. 
 H6: ESRD participants were expected to score significantly differently from the healthy 
controls on measures of depression, social functioning, health related quality of life, and sleep 
quality. The t-test analysis confirmed that in all measures except depression, the ESRD 
participants were significantly different from healthy controls (p < .05). In the measure of 
depression, ESRD participants scored only marginally significantly differently (p = .075) than 
healthy controls. In all measures, the ESRD participants scored worse than control participants 
(i.e. higher depression scores than healthy controls, lower social functioning scores than healthy 
controls, etc.)
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CHAPTER V 
 
DISCUSSION 
 
Interpretation of Findings 
The results of the t-test suggest some important factors that should be addressed when 
interpreting the findings of this study. While the ESRD group was marginally significantly 
different from the healthy group on the measure of depression, the mean of the ESRD group was 
only 15.8. The literature on the measure indicates that any score greater than or equal to 16 is 
considered showing clinical depression symptoms (Eaton et al., 2004). Therefore, while the 
ESRD participants may be different from the healthy control group, it is important to note that 
they are not showing very high symptoms of depression, as would be expected from the 
literature. This sample of ESRD participants may reflect a group of “super patients” that feel 
well enough to participate in a research study and may not be very representative of the ESRD 
population as a whole. 
The results of the univariate regression analysis showed social functioning, overall 
quality of life, and age (marginally) to be significantly related to depression scores. For all of 
these factors the relationship to depression was negative, meaning that as social functioning, 
overall quality of life, or age increased, depression levels decreased. While many of these 
findings were expected based on the literature, the negative relationship between age and 
depression is interesting because the relationship is possibly counterintuitive compared to other 
studies on age effects in other populations. These results are consistent however with Laudanski 
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et al.’s (2013) findings that younger ESRD patients use more emotional preoccupation to cope 
with the disease than older ESRD patients. These results suggest it is possible that younger adults 
are more affected by the disease due to their life circumstances (i.e. taking care of their family) 
compared to older adults who may be less relied on by family members.  
The results of the length of time on dialysis analyses were not significant; however, these 
results may warrant more consideration than other non-significant findings. The inclusion criteria 
listed in Appendix A, require the patients to be on dialysis for greater than three months. This 
criterion may have limited the sample to exclude a crucial period of time at first diagnosis where 
having ESRD can be the most impactful mentally. The length of time on dialysis may not be as 
much of a factor after being on dialysis for greater than three months, however, time since 
diagnosis may have an entirely different impact. The subjective response to being diagnosed may 
play a larger role in depression of ESRD patients, due to the substantial impact the disease 
treatment can have on one’s life. 
 Multivariate analyses were used to determine the relationship between two or more 
variables while holding other variables in the analysis constant. This allows us to assess if the 
relationship is due to the variable, or other factors influencing the relationship. It also allows us 
to examine the relationship of a combination of the variables, to determine if a combination of 
variables has a stronger relationship to depression over any variable alone. The results of these 
analyses found the combination of social functioning, sleep quality, and age to account for the 
greatest amount of variability in the depression scores of the sample. The adjusted multiple r-
square of .778 estimates what percentage of the differences that these variables would account 
for if applied to the population based on the number of predictors, and sample size. The high 
adjusted multiple r-square is particularly important in this study because of the unusually small 
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sample size, and suggests that these three factors could provide a focus for caretakers of ESRD 
patients. However, as mentioned previously, these results should be interpreted with caution due 
to the type of participants that were recruited for this study. 
 
Limitations 
 The most outstanding limitation in the present study is the sample size of 10 for kidney 
disease participants and 5 for healthy controls. Sample sizes did not meet the projected amount 
during the data collection period due to withdrawals of consent, missed appointments, and 
difficulty of recruitment. As part of a larger study, recruitment and appointment scheduling 
involved many groups and individuals to be available, and required the participants to show up 
for their scheduled appointment. Along with a small sample size, the unequal distribution of 
males (n = 8) to females (n = 2) as well as the missing data on length of time on dialysis for two 
participants, made the analysis of gender as a factor unfeasible and any analysis that included 
length of time on dialysis was restricted to 8 participants, further shrinking an already small 
sample size. Furthermore, the sample used in this study was made up of ESRD patients that were 
willing and able to participate in the study. This factor may have influenced the results of the 
analysis as these ESRD patients might be considered “super subjects” that are healthier than 
other ESRD patients, and who may not be representative of the population as a whole 
consequently.  
Another limitation of the present study involves the measures that were used. The SF-36 
health related quality of life scale, and subscale measure of social functioning may not be the 
strongest measure of quality of life and social functioning in the ESRD population according to a 
review by Glover et al. (2011) comparing the content validity of six different quality of life 
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measures across various studies on quality of life in the ESRD population. Out of 378 articles 
reviewed, it was found that the SF-36 measure was the most commonly used, however, the 
KDQOL-SF had the highest content validity of all six measures reviewed. This disease specific 
measure may provide a more valid and accurate assessment of quality of life, compared to a 
generic measure, in ESRD patients specifically. However, while a disease specific measure will 
most likely be more valid in studying the ESRD population, there are some circumstances where 
a generic measure may also be appropriate, most notably in a comparison to other chronic 
disease populations. Disease specific measures do not allow for these comparisons across 
populations, therefore, in these circumstances a generic measure may be more appropriate. In 
these instances, the review by Glover et al. (2011) found the World Health Organization Quality 
of Life assessment, abbreviated version (WHOQOL-BREF) to be a more appropriate measure in 
respect to content validity compared to the other general health related quality of life 
questionnaires reviewed, including the SF-36. The authors suggest that the widespread use of the 
SF-36 in this population is the result of it being used commonly in studies of other chronic 
diseases and that its data is easy to compare across different groups. However, the authors 
caution the use of this measurement because it does not measure all aspects of quality of life of 
the ESRD population, and suggest the use of the WHOQO-BREF as it is similarly short, and 
easy to administer, while also providing a measure of the aspects of quality of life that the SF-36 
misses (Glover et al., 2011). This review provides a claim that future studies should be used to 
strengthen the body of research on alternative quality of life measures for a better comparison 
between the many different measures. 
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Recommendations for Future Studies 
Future studies should examine these factors in a larger sample size, using a disease 
specific measure of social functioning instead of a generic measure and subscales of quality of 
life. Although not all factors were significant, a larger sample size with more accurate measures 
could find vastly different results, while also providing more data on other quality of life 
measures in the ESRD population. These results could be used in comparison to other studies 
using a generic quality of life measure to determine if a disease specific measure provides more 
accurate results in studies on this population. 
Furthermore, longitudinal studies examining the impact of these same factors included in 
the present study over a period of time would help determine which of these events was the 
original problem. With correlational data, no inference can be made about which factor caused 
which. Longitudinal analyses could answer some important questions, such as, “Does depression 
cause poor sleep quality? Or does poor sleep quality cause depression?” With answers to these 
questions, caretaking strategies could better focus on the original problem, rather than treating 
the symptoms.  
 Additionally, objective measures of social support, quality of life, sleep quality, and 
depression should be considered in future studies. All measures included in the present study 
were self-report. The discrepancy between perceived support or quality of life and actual support 
or quality of life as measured by family members and friends could provide more insight as to 
what treatments may be most effective. For example, increasing the presence of available social 
support may not be an effective treatment option if the patient claims to have a different level of 
support than what family members and friends report. The problem in these cases may be a 
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perception issue, rather than an actual level of support issue, which should be an important factor 
to consider when deciding treatment options for these patients. 
Other studies could involve testing the effectiveness of interventions based on these 
results to determine if there are any effective augmentations to current depression treatments for 
kidney disease patients suffering from depression symptoms. An example of these studies 
include testing the effectiveness of interventions to increase sleep quality in kidney disease 
patients, a goal of the larger study (Tumlin et al., 2012) from which the present study was 
conducted. With the increasing life expectancy of these patients, it is crucial to conduct these 
studies to determine the safest and most efficient way to lowering depression prevalence and 
increasing quality of life in this population. Future studies looking at similar constructs could 
also be expanded to other chronic diseases with similar statistics as ESRD populations to 
determine if these factors are disease specific or can be generalized to other populations. 
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APPENDIX A 
 
INCLUSION/EXCLUSION CRITERIA
35 
 
Inclusion Criteria: 
1) Patient age > 18 and <85 years of age 
2) Patients with CKD  or ESRD with eGFR < 30 mls/min 
3) If receiving hemodialysis, patients must be on treatment > 3 months 
4) Normal healthy controls must be without a known history of CKD and be willing to 
have formal PSG test and plasma melatonin measurements 
 
Exclusion Criteria: 
1) Patients receiving outpatient hemodialysis for < 3 months 
2) Patients with estimated GFR by Cockcroft Gault > 30 mls/min 
3) Patients receiving beta blocker therapy within one month of randomization 
4) Patients receiving Nifedipine therapy within one month randomization 
5) Patients on peritoneal dialysis 
6) Patient with chronic home oxygen supplementation 
7) Patients receiving chronic home CPAP therapy 
8) Patients actively receiving outpatient sleep medications 
9) Patients with diabetic gastroparesis unresponsive to medication 
10) Patients with known pregnancy or unwilling to use contraception during the course of 
the study 
11) Patients with a functioning renal allograft 
12) Patient currently receiving long-term immunosuppressive therapy.  Patients receiving 
low dose prednisone (10mg or less per day) will not be excluded from this trial 
13) Unable to give informed consent 
36 
 
APPENDIX B 
 
SF-36 HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE (SF-36)
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SF-36 
 
 
Name_____________________________________ 
Date______________________________________ 
Moderator__________________________________ 
 
 
1) In general, would you say your health is: (circle one) 
a) Excellent 
b) Very good 
c) Good 
d) Fair 
e) Poor 
 
2) Compared to one year ago, how would you rate your health in general now? (circle one) 
a) Much better now than one year ago 
b) Somewhat better now than one year ago 
c) About the same 
d) Somewhat worse now than one year ago 
e) Much worse now than one year ago 
 
Place a check mark or “X” in the appropriate box. Only select one for each question. 
 
In a typical day, does your health now limit you 
in these activities? If so, how much? 
Yes, 
Limited a 
Lot 
Yes, Limited 
a Little 
No, Not 
Limited at All 
3. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports 
   
4. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf 
   
5. Lifting or carrying groceries    
6. Climbing several flights of stairs    
7. Climbing one flight of stairs    
8. Bending, kneeling, or stooping    
9. Walking more than one mile    
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Place a check mark or “X” in the appropriate box. Only select one for each question. 
In a typical day, does your health now limit 
you in these activities? If so, how much? 
Yes, Limited 
a Lot 
Yes, Limited 
a Little 
No, Not 
Limited at All 
10. Walking several blocks    
11. Walking one block    
12. Bathing or dressing yourself    
 
 
Place a check mark or “X” in the appropriate box.  Only select one for each question. 
 
During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical 
health? 
Yes No 
13. Cut down on the amount of time you spent on work other activities 
  
14. Accomplished less than you would like 
  
15. Were limited in the kind of work or other activities 
  
16. Had difficulty performing the work or other activities (for example, it 
took extra effort) 
  
 
 
Place a check mark or “X” in the appropriate box.  Only select one for each question. 
 
During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
Yes No 
17. Cut down on the amount of time you spent on work other activities   
18. Accomplished less than you would like 
  
19. Were limited in the kind of work or other activities 
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20. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups?  
(Circle one) 
a) Not at all 
b) Slightly 
c) Moderately 
d) Quite a bit 
e) Extremely 
 
21. How much bodily pain have you had during the past 4 weeks? (Circle one) 
a) None 
b) Very mild 
c) Mild 
d) Moderate 
e) Severe 
f) Very severe 
 
22. During the past 4 weeks, how much pain interfered with your normal work (including both 
work outside the home and house work)? (Circle one) 
a) Not at all 
b) A little bit 
c) Moderately 
d) Quite a bit 
e) Extremely 
 
 
Place a check mark or “X” in the appropriate box.  Only select one for each question. 
 
During the past 4 weeks… 
All of 
the Time 
Most of 
the Time 
A Good 
Bit of 
the Time 
Some of 
the Time 
A Little 
Bit of 
the Time 
None of 
the Time 
23. Did you feel full of pep? 
      
24. Have you been a nervous 
person? 
      
25. Have you felt so down in 
the dumps that nothing could 
cheer you up? 
      
26. Have you felt calm and 
peaceful? 
      
27. Did you have a lot of 
energy? 
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Place a check mark or “X” in the appropriate box. Only select one for each question. 
During the past 4 weeks… 
All of 
the Time 
Most of 
the Time 
A Good 
Bit of 
the Time 
Some of 
the Time 
A Little 
Bit of 
the Time 
None of 
the Time 
28. Have you felt 
downhearted and blue? 
      
29. Did you feel worn out? 
      
30. Have you been a happy 
person? 
      
31. Did you feel tired? 
      
 
 
32. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)?  
(Circle one) 
a) All of the time 
b) Most of the time 
c) Some of the time 
d) A little of the time 
e) None of the time 
 
 
Place a check mark or “X” in the appropriate box. Only select one for each question. 
 
How true or false is each of the following 
statements for you? 
Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
33. I seem to get sick a little easier than 
other people 
     
34. I am as healthy as anybody I know 
     
35. I except my health to get worse 
     
36. My health is excellent 
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APPENDIX C 
 
CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE,  
 
REVISED VERSION (CESD-R)
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CESD-R 
 
Name_____________________________________ 
Date______________________________________ 
Moderator__________________________________ 
 
 
Place a check mark or “X” in the appropriate box. Only select one for each question. 
Below is a list of the ways you might 
have felt or behaved.  Please check 
the boxes to tell me how often you 
have felt this way in the past week or 
so. 
Last Week 
Nearly 
every 
day for 2 
weeks 
Not at all 
or Less 
than 1 
day 
1-2 days 3-4 days 5-7 days 
1) My appetite was poor. 
     
2) I could not shake the blues. 
     
3) I had trouble keeping my 
mind on what I was doing. 
     
4) I felt depressed. 
     
5) My sleep was restless. 
     
6) I felt sad. 
     
7) I could not get going. 
     
8) Nothing made me happy. 
     
9) I felt like a bad person. 
     
10) I lost interest in my usual 
activities. 
     
11) I slept much more than 
usual.  
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12) I felt that I was moving too 
slowly. 
     
13) I felt fidgety. 
     
14) I wished I were dead. 
     
 
Place a check mark or “X” in the appropriate box. Only select one for each question. 
Below is a list of the ways you might 
have felt or behaved.  Please check 
the boxes to tell me how often you 
have felt this way in the past week or 
so. 
Last Week 
Nearly 
every 
day for 2 
weeks 
Not at all 
or Less 
than 1 
day 
1-2 days 3-4 days 5-7 days 
15) I wanted to hurt myself. 
     
16) I was tired all the time. 
     
17) I did not like myself. 
     
18) I lost a lot of weight 
without trying to. 
     
19) I had a lot of trouble 
getting to sleep. 
     
20) I could not focus on the 
important things. 
     
 
44 
 
APPENDIX D 
 
PITTSBURGH SLEEP QUALITY INDEX (PSQI)
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PSQI 
 
Number__________________ 
Date_____________________ 
 
During the past month, 
1. When have you usually gone to bed (what time)? _________________ 
2. How long (in minutes) has it taken you to fall asleep each night? ________________ 
3. When have you usually gotten up in the morning? ____________________ 
4. How many hours of actual sleep do you get at night? (This may be different than the 
number of hours you spend in bed) _________________ 
5. During the past month, how often have you had 
trouble sleeping because you… 
Not 
during 
the past 
month 
Less 
than 
once a 
week 
Once or 
twice a 
week 
Three or 
more 
time a 
week 
a. Cannot get to sleep within 30 minutes     
b. Wake up in the middle of the night or early 
morning 
    
c. Have to get up to use the bathroom     
d. Cannot breathe comfortably     
e. Cough or snore loud     
f. Feel too cold     
g. Feel too hot     
h. Have bad dreams     
i. Have pain     
j. Other reason(s), please describe, including how 
often you have trouble sleeping because of this 
reason(s): 
    
6. During the past month, how often have you taken 
medicine (prescribed or “over the counter”) to help 
you sleep? 
    
7. During the past month, how often have you had 
trouble staying awake while driving, eating meals, or 
engaging in social activity 
    
8. During the past month, how much of a problem has it 
been for you to keep your enthusiasm to get things 
done? 
    
 
 Very 
Good 
Fairly 
Good 
Fairly 
Bad 
Very 
Bad 
9. During the past month, how would you rate your 
sleep quality overall? 
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APPENDIX E 
 
NORMAL PROBABILITY PLOTS OF VARIABLES
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Social Functioning 
 
 
 
 
Overall Quality of Life 
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Sleep Quality 
 
 
 
 
Time on Dialysis 
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Age 
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APPENDIX F 
 
INFORMED CONSENT DOCUMENT
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Informed Consent Form 
 
While we hope that you will complete the attached study, your participation is voluntary. 
You may elect not to participate at any time. In addition, if you do not feel comfortable 
answering any of the questions you may leave that question blank and continue with the 
rest of the study. The information you provide will be anonymous and we do not ask you to 
identify yourself in any way. Boredom and Nasal Dryness are the only risks associated with 
your participation in this project. You will not receive any direct benefit from participating 
in the study.  
 
This first part of the study will ask you to respond to questions about sleeping, general 
health, and recent feeling or behaviors. The second part of the study will ask you to identify 
smells located on scratch and sniff booklets. The third part will ask you to respond whether 
or not you detected an odor in a tube. The last thing the study asks you to do is fill out a 
demographic page. The demographic information will ask about age, gender, ethnicity, 
occupation, education, smoker vs. non-smoker, history with health illnesses, and any 
medications being taken. These questions will help us to interpret the results of the rest of 
the study. 
 
We expect that it will take approximately 1 hour to participate in this study.  
 
Remember, this is an anonymous survey, so please do not write your name anywhere other 
than this page. 
 
You may also request a copy of this form for your records. 
 
Who to Contact 
If you have any questions or would like to obtain a report of this research study when the 
results have been completed, please contact Dr. Nicky Ozbek (423-425-4262), Department 
of Psychology, University of Tennessee at Chattanooga.  This survey is being conducted as 
part of a Student Senior Research Project.  This project meets the requirements for 
approval by the UTC IRB and contact can be made to the UTC IRB through Director Lindsay 
Pardue (423-425-4443) and Chair Dr. Bart Weathington (423-425-4289). 
 
Thank you for participating in our research! 
 
 
Name (Print) _____________________________________________ Date________________ 
 
Signature ________________________________________________ Date________________ 
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IRB APPROVAL DOCUMENTS
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MEMORANDUM 
    
 
 
TO:   Dr. Nicky Ozbek        IRB # 12-196 
  Dr. James Tumlin 
   
  
FROM: Lindsay Pardue, Director of Research Integrity 
  Dr Bart Weathington, IRB Committee Chair  
 
DATE: November 28, 2012 
 
 
SUBJECT: IRB Application # 12-196: Olfactory Sensitivity and Depression in Dialysis 
Patients                        
 
The IRB Committee Chair has reviewed and approved your application and assigned you the IRB number 
listed above.  You must include the following approval statement on research materials seen by 
participants and used in research reports: 
 
The Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has 
approved this research project # 12-196. 
 
Since your project has been deemed exempt, there is no further action needed on this proposal unless 
there is a significant change in the project that would require a new review.  Changes that affect risk to 
human subjects would necessitate a new application to the IRB committee immediately.   
 
Please remember to contact the IRB Committee immediately and submit a new project proposal for 
review if significant changes occur in your research design or in any instruments used in conducting the 
study. You should also contact the IRB Committee immediately if you encounter any adverse effects 
during your project that pose a risk to your subjects. 
 
For any additional information, please consult our web page http://www.utc.edu/irb or email us at: 
instrb@utc.edu . 
 
Best wishes for a successful research project. 
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MEMORANDUM 
  
 
 
TO:   Dr. Nicky Ozbek       IRB # 12-196 
       
 
FROM: Lindsay Pardue, Director of Research Integrity 
 Dr. Bart Weathington, IRB Committee Chair 
 
DATE: January 10, 2013 
 
SUBJECT: IRB #:12-196: Olfactory Sensitivity and Depression in Dialysis Patients                        
 
 
The Institutional Review Board has reviewed and approved the following changes for the IRB project 
listed below: 
 
 We would like to add the odor threshold test and the scratch and sniff cards for the odorant 
vanilla. Neither the WUTC odor threshold test nor the vanilla scratch and sniff cards had been 
available at the time of the original submission of the Melatonin grant profile. The addition of 
these tests instruments requires the patient consent form to include their administration in the 
consent. Approval of this modification has been obtained from the IRB of the UT College of 
Medicine scientific review board. A copy of the approval letter is attached. 
 
You must include the following approval statement on research materials seen by participants and used 
in research reports: 
 
The Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has 
approved this research project # 12-196. 
 
Please remember that you must complete a Certification for Changes, Annual Review, or Project 
Termination/Completion Form when the project is completed or provide an annual report if the project 
takes over one year to complete.  The IRB Committee will make every effort to remind you prior to your 
anniversary date; however, it is your responsibility to ensure that this additional step is satisfied.   
 
Please remember to contact the IRB Committee immediately and submit a new project proposal for 
review if significant changes occur in your research design or in any instruments used in conducting the 
study. You should also contact the IRB Committee immediately if you encounter any adverse effects 
during your project that pose a risk to your subjects. 
 
For any additional information, please consult our web page http://www.utc.edu/irb or email 
instrb@utc.edu  
 
Best wishes for a successful research project. 
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